$29.70
+3.99%Oct 24, 2026, 11:00 UTC
Nanobiotix S.A. announced final Phase 1 Study 1100 data for JNJ-1900 (NBTXR3) with immune checkpoint inhibitors in 24 patients with anti-PD-1-resistant advanced primary cutaneous melanoma, reporting a 41.7% overall response rate, including four complete responses, a 75% disease control rate, and median overall survival of 17.8 months.
Source:Oct 1, 2026, 20:15 UTC
Nanobiotix appointed Arnd Christ as chief financial officer and member of its executive board, effective October 1, 2026, succeeding Bart Van Rhijn.
Source:Sep 24, 2026, 20:15 UTC
Nanobiotix reported its operational progress and financial results for the first half of 2026.
Source:Sep 14, 2026, 06:00 UTC
Nanobiotix announced complete full-cohort Phase 1 results for JNJ-1900 (NBTXR3) in inoperable, recurrent non-small cell lung cancer, presented at the IASLC 2026 World Conference on Lung Cancer.
Source:Jun 2, 2026, 20:30 UTC
Nanobiotix provided an operational update and reported financial results for the first quarter of 2026.
Source: